ACE and chronic kidney disease: We also found a decrease in prescriptions of non-recommended drugs, such as NSAIDs, in CKD stage 4–5, along with a reduction in the dual use of renin–angiotensin system blockers (ACE inhibitors and ARBs) and no difference in NSAID prescriptions among patients seen by kidney specialists or GPs.